Takeda Pharmaceutical CoTSE:4502 +0.65%67 FCF Margin % is 0.93% as of Mar. 2026, which is 93% below its 10-year median of 13.82. GuruFocus rates TSE:4502 with a GF Score™ of 67/100 and a GF Value™ of 円4,531.71 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 958 Drug Manufacturers companies, Takeda Pharmaceutical Co ranks better than 78.91% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takeda Pharmaceutical Co FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Takeda Pharmaceutical Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Takeda Pharmaceutical Co (TSE:4502) has a FCF Margin % of 0.93% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Takeda Pharmaceutical Co and its competitors. This is 93% below median its historical median of 13.82. Over the past decade, Takeda Pharmaceutical Co's FCF Margin % has ranged from 5.53 to 26.26. According to the industry distribution chart, Takeda Pharmaceutical Co ranks #202 out of 958 companies in the Drug Manufacturers industry, placing it in the top 21.1%.
Is Takeda Pharmaceutical Co's FCF Margin % too high?
Takeda Pharmaceutical Co's current FCF Margin % of 0.93% is 93% below median its 10-year median of 13.82. Over the past 10 years, this metric has ranged from a low of 5.53 to a high of 26.26. The Drug Manufacturers industry median FCF Margin % is 2.45. Takeda Pharmaceutical Co's value of 0.93% is 62% below this industry median. Based on the distribution chart, Takeda Pharmaceutical Co ranks #202 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Takeda Pharmaceutical Co has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Takeda Pharmaceutical Co ranks #202 out of 958 companies for FCF Margin %. This places Takeda Pharmaceutical Co in the top 21% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.45. Takeda Pharmaceutical Co's value of 0.93% is 62% below this benchmark. Historically, Takeda Pharmaceutical Co's own FCF Margin % has ranged from 5.53 to 26.26 over the past decade. While the company's 10-year median is 13.82 vs. the industry median of 2.45, Takeda Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Takeda Pharmaceutical Co's current FCF Margin % of 0.93% is 62% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Takeda Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Takeda Pharmaceutical Co's current FCF Margin % is 0.93%, which is 93% below median its own 10-year median of 13.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (TSE:4502) is currently considered Modestly Overvalued. The stock's GF Value™ is 円4,531.71, compared to a current price of 円5,087.00 — trading 12.3% above its estimated fair value. The current FCF Margin % is 0.93%, which is 93% below median its 10-year median of 13.82 and 62% below the Drug Manufacturers industry median of 2.45. Takeda Pharmaceutical Co's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Takeda Pharmaceutical Co (TSE:4502), the current FCF Margin % is 0.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takeda Pharmaceutical Co (TSE:4502) Overvalued in 2026?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円5,087.00 is trading 12.3% above its estimated GF Value™ of 円4,531.71.
GuruFocus considers Takeda Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for TSE:4502:
FCF Margin %: 0.93% (93% below median its 10-year median of 13.82)
GF Value™: 円4,531.71 vs. price of 円5,087.00 (12.3% above fair value)
Industry Position: 62% below the Drug Manufacturers median (#202 of 958)
No single metric tells the full story. See the TSE:4502 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
67GF Score
Get the complete analysis for TSE:4502
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4502 has been successfully added to your 
